Equities
Consumer ServicesFood & Drug Retailers
  • Price (USD)205.37
  • Today's Change-1.05 / -0.51%
  • Shares traded1.28m
  • 1 Year change+30.79%
  • Beta0.8733
Data delayed at least 15 minutes, as of Aug 04 2021 21:10 BST.
More ▼
Take Action
Take Action
Add this security to watchlist, portfolio, or create an alert to track market movement

Profile data is unavailable for this security.

About the company

McKesson Corporation is a healthcare supply chain management solution, retail pharmacy, community oncology and specialty care, and healthcare information technology company. The Company provides medicines, medical products and healthcare services by partnering with pharmaceutical manufacturers, providers, pharmacies, governments and other organizations in healthcare. It operates through three segments: United States Pharmaceutical and Specialty Solutions, European Pharmaceutical Solutions and Medical-Surgical Solutions. The United States Pharmaceutical and Specialty Solutions segment distributes pharmaceutical and other healthcare related products and provides pharmaceutical solutions to life sciences companies. European Pharmaceutical Solutions segment provides distribution and services to wholesale, institutional and retail customers. Medical-Surgical Solutions segment distributes medical-surgical supplies and provides logistics and other services to healthcare providers.

  • Revenue in USD (TTM)238.23bn
  • Net income in USD-4.54bn
  • Incorporated1994
  • Employees59.00k
  • Location
    Mckesson Corp6555 State Highway 161IRVING 75039-2402United StatesUSA
  • Phone+1 (972) 446-4800
  • Fax+1 (302) 636-5454
  • Websitehttp://www.mckesson.com
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Elanco Animal Health Inc3.86bn-572.00m17.37bn9.40k--2.17265.574.50-1.21-1.218.3516.930.28881.564.53410,383.00-4.28---4.77--50.6749.96-14.83-5.240.944-0.06380.4349--6.592.39-924.89--25.44--
EXACT Sciences Corporation1.71bn-864.77m17.92bn4.80k--5.03--10.47-5.47-5.4710.5720.710.30594.878.77356,582.90-15.45-16.06-16.80-17.6475.5374.55-50.52-43.592.34-171.830.384--70.19106.79-910.24--84.98--
BIO-TECHNE Corp847.84m184.12m18.72bn2.30k104.8612.1569.8822.084.594.5921.1139.620.41522.656.16368,625.209.007.779.598.2467.2666.5021.6818.973.3214.450.122240.193.4610.31138.7016.2821.050.157
ICON PLC3.19bn363.86m19.43bn16.07k35.75--44.806.096.836.8359.88--------202,880.50--13.41--19.5028.4233.2511.4413.62--15.52--0.00-0.304812.17-11.146.770.5273--
10X Genomics Inc332.76m-533.14m19.60bn946.00--26.00--58.92-5.03-5.033.206.870.42542.097.54390,564.60-68.16---77.00--81.84---160.22--5.87-532.830.00--21.53---1,636.68------
Charles River Laboratories Intl. Inc3.04bn375.07m20.67bn18.40k55.839.4633.466.797.377.3759.8343.490.552510.725.28165,295.706.876.688.007.9537.1537.2212.4410.581.534.810.49880.0011.5516.4944.5519.3821.37--
Catalent Inc3.76bn496.80m20.81bn13.90k41.285.6026.715.542.962.9622.4623.940.47425.734.30270,316.507.033.108.073.5333.2031.5314.825.881.955.670.44180.0022.8911.0725.91-3.9927.00--
Alnylam Pharmaceuticals, Inc.687.53m-886.68m21.02bn1.45k--24.85--30.57-7.60-7.605.897.200.19981.218.00473,182.40-25.76-35.41-29.83-40.1385.73---128.97-368.564.76-6.310.3367--124.2864.353.14--40.29--
Horizon Therapeutics PLC2.19bn280.04m22.42bn1.64k86.535.8139.7210.251.151.159.9917.160.35973.505.041,567,689.004.611.345.191.6075.5167.8112.814.262.068.030.40080.0069.2623.79-31.9858.0488.40--
Gartner Inc4.38bn571.91m25.28bn15.60k45.2546.8331.985.776.496.4949.236.270.6256--3.99280,688.108.172.7213.384.7668.7963.3213.064.17--7.810.82360.00-3.4413.6414.348.7212.71--
AmerisourceBergen Corp.196.28bn-3.75bn25.41bn22.00k------0.1295-18.43-18.43953.13-1.374.4115.8612.728,921,921.00-8.410.1172-31.670.48112.832.81-1.910.02550.682316.441.02655.335.746.91-516.53--9.817.43
Seagen Inc2.38bn597.27m28.78bn2.09k48.558.4843.6412.073.263.2613.0418.650.77932.237.121,139,333.0019.53-0.423122.12-0.48988.1690.3925.06-0.71686.77--0.00--137.3245.22486.81--43.82--
McKesson Corporation238.23bn-4.54bn31.93bn59.00k------0.134-28.57-28.581,478.99-0.13293.7712.5712.184,037,763.00-6.870.5468-23.811.615.105.37-1.820.1520.592615.200.8317196.163.114.53-600.88---1.099.80
DuPont de Nemours Inc18.46bn1.28bn39.59bn34.00k33.941.4511.052.142.199.9928.3351.230.32793.485.69542,911.802.330.05352.640.068334.5627.557.110.27671.993.910.279---5.18-16.00-308.73---20.45-25.30
Data as of Aug 04 2021. Currency figures normalised to Mckesson Corp's reporting currency: US Dollar USD

Institutional shareholders

36.86%Per cent of shares held by top holders
HolderShares% Held
The Vanguard Group, Inc.as of 31 Mar 202115.24m9.86%
BlackRock Fund Advisorsas of 31 Mar 20218.41m5.44%
SSgA Funds Management, Inc.as of 31 Mar 20216.95m4.50%
JPMorgan Investment Management, Inc.as of 31 Mar 20216.68m4.32%
Massachusetts Financial Services Co.as of 31 Mar 20215.85m3.78%
Pzena Investment Management LLCas of 31 Mar 20213.05m1.97%
Geode Capital Management LLCas of 31 Mar 20212.88m1.86%
Boston Partners Global Investors, Inc.as of 31 Mar 20212.86m1.85%
Fidelity Management & Research Co. LLCas of 31 Mar 20212.66m1.72%
Nordea Investment Management AB (Denmark)as of 30 Jun 20212.44m1.58%
More ▼
Data from 31 Mar 2021 - 30 Jun 2021Source: FactSet Research Systems Inc.
Refinitiv, an LSEG business
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.